2021

Nakatani Y, Sridi-Cheniti S, Cheniti G et al. Pulsed field ablation prevents chronic atrial fibrotic changes and restrictive mechanics after catheter ablation for atrial fibrillation. Europace (2021) 00, 1–10. doi:10.1093/europace/euab155

Kawamura I, Neuzil P, Shivamurthy P et al. Does pulsed field ablation regress over time? A quantitative temporal analysis of pulmonary vein isolation. Heart Rhythm. 2021 Jun;18(6):878-884. doi: 10.1016/j.hrthm.2021.02.020. Epub 2021 Feb 27.

Reddy VY, Dukkipati SR, Neuzil P, et al. Pulsed Field Ablation of Paroxysmal Atrial Fibrillation: 1-Year Outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC: Clinical Electrophysiology. Volume 7, Issue 5, May 2021, Pages 614-627. oi.org/10.1016/j.jacep.2021.02.014

Kawamura I, Neuzil P, Shivamurthy P, et al. How does the level of pulmonary venous isolation compare between pulsed field ablation and thermal energy ablation (radiofrequency, cryo, or laser)? EP Europace, euab150. doi.org/10.1093/europace/euab150

Cochet H, Nakatani Y, Sridi-Cheniti S, et al. Pulsed field ablation selectively spares the oesophagus during pulmonary vein isolation for atrial fibrillation. Europace (2021) 00, 1–9 CLINICAL RESEARCH doi:10.1093/europace/euab090

2020

For more information about The ADVENT Trial, including sites where enrollment is active, please CLICK HERE.

Reddy VY, Anic A, Koruth JS, et al. Pulsed Field Ablation in Patients with Persistent Atrial Fibrillation. Journal of the American College of Cardiology. 2020 Sep, 76 (9) 1068–1080

Kuroki K, Whang W, Eggert C, et al. Ostial dimensional changes after pulmonary vein isolation: Pulsed field ablation vs radiofrequency ablation. Heart Rhythm 2020 May, doi.org/10.1016 /j.hrthm.2020.04.040

2019

For more information about The ADVENT Trial, including sites where enrollment is active, please CLICK HERE.

Reddy V, Neuzil P, Koruth J, et al. Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation. Journal of the American College of Cardiology. 2019 Jul, 74 (3) 315–326

2018

For more information about The ADVENT Trial, including sites where enrollment is active, please CLICK HERE.

Reddy V, Koruth J, Jais P, et al. Ablation of Atrial Fibrillation With Pulsed Electric Fields: An Ultra-Rapid, Tissue-Selective Modality for Cardiac Ablation. JACC: Clinical Electrophysiology. May 2018, 674; DOI:10.1016/j.jacep.2018.04.005

2020

For more information about The ADVENT Trial, including sites where enrollment is active, please CLICK HERE.

Koruth J, Kuroki K, Kawamura I, et al. Pulsed Field Ablation vs Radiofrequency Ablation: Esophageal Injury in a Novel Porcine Model. Circulation: Arrhythmia and Electrophysiology. 2020;13:e008303. doi.org/10.1161/CIRCEP.119.008303

2019

For more information about The ADVENT Trial, including sites where enrollment is active, please CLICK HERE.

Koruth J, Kuroki K, Iwasawa J, et al. Preclinical Evaluation of Pulsed Field Ablation: Electrophysiological and Histological Assessment of Thoracic Vein Isolation. Circulation: Arrhythmia and Electrophysiology. 2019;12:e007781. doi.org/10.1161/CIRCEP.119.007781

Koruth J, Kuroki K, Iwasawa J, et al. Endocardial ventricular pulsed field ablation: a proof-of-concept preclinical evaluation. EP Europace. 2019. doi.org/10.1093/europace/euz341

2019

For more information about The ADVENT Trial, including sites where enrollment is active, please CLICK HERE.

Jais P, Takigawa M, Sacher F, et al. Comparison of Biphasic and Monophasic Pulsed Field Ablation in an Animal Model, AFS2019-26, J Cardiovasc Electrophysiolog. 2019;1-28 (abstr)

Kuroki K, Koruth J, Iwasawa J, et al. Pulmonary Vein Isolation with Biphasic Pulsed Field Ablation: A Pre-Clinical Comparison with Irrigated Radiofrequency Ablation, AFS-2019-14, J Cardiovasc Electrophysiolog. 2019;1-28 (abstr)

Takigawa M, Vlachos K, Viswanathan R, et al. Acute Results of Superior Vena Cava and Pulmonary Vein Isolation Using Pulsed Electric Field Ablation in a Swine Model, B-PO02-004, Heart Rhythm; 15(5), S178-179 (abstr)

Vlachos K, Takigawa M, Bourier F, et al. Safety of Pulmonary Vein and SVC Ablation Using Pulsed Electric Field Energy, B-PO03-114, Heart Rhythm; 15(5), S330-331 (abstr)

Iwasawa J, Koruth J, Kuroki K, et al. Pulmonary Vein Isolation in Seconds: Pre-clinical Feasibility and Safety Using Pulsed Electric Field Energy in a Porcine Model, B-PO02-023, Heart Rhythm; 15(5), S187 (abstr)

Mickelsen S, Lumpp W, Chaudhary A, et al. A catheter-based epicardial pulmonary vein isolation procedure: the Iowa approach, PO01-134, Heart Rhythm; 13(5), S98-S147 (abstr)

Mickelsen S, McElderry H, Sauter E, et al. Preclinical safety of novel catheter-based system for intra-pericardial circumnavigation of the left atrium: first steps of the Iowa approach, PO03-142, Heart Rhythm; 13(5), S251-S339 (abstr)

Kusa S, Koruth J, Enomoto Y, et al. Posterior left atrial ablation by epicardial electroporation in a porcine model, PO03-143, Heart Rhythm; 13(5), S251–S339 (abstr)

McElderry H, Walcott G, Viswanathan R, et al. Safety of pulsed electric field ablation in direct application to the porcine esophagus, AFS-2018-7, J Cardiovasc Electrophysiol. 2018;29:657–678. (abstr)

McElderry H, Walcott G, Koruth J, et al. Investigation of pulsed electric fields for pulmonary vein and left atrial wall ablation in an acute and chronic porcine model, AFS-2018-5, J Cardiovasc Electrophysiol. 2018;29:657–678. (abstr)

Mickelsen S, Long G, Allamargot C, et al. Feasibility of synchronized ultra-short impulse high-voltage direct current technique in left atrial epicardial catheter-based ablation: pericardial atrial fibrillation ablation. PO05-104, Heart Rhythm; 11(5), S451-492 (abstr)

Neuzil P, Petru J, Funosaki M, et al. Pulsed Field Ablation for Pulmonary Vein Isolation in Humans: Endoscopic Observations of the Esophagus AFS-2019-27, J Cardiovasc Electrophysiolog. 2019;1-28 (abstr)

Neuzil P, Petru J, Funosaki M, et al. Effect of Pulsed Field Ablation on the Phrenic Nerve During Pulmonary Vein Isolation: Pre-Clinical and Clinical Evaluation AFS-2019-32, J Cardiovasc Electrophysiolog. 2019;1-28 (abstr)

Kuroki K, Neuzil P, Petru J, et al. Does Pulsed Field Ablation to Treat Atrial Fibrillation in Humans Cause Pulmonary Vein Stenosis?, AFS-2019-30, J Cardiovasc Electrophysiolog. 2019;1-28 (abstr)

2018

For more information about The ADVENT Trial, including sites where enrollment is active, please CLICK HERE.

McElderry H, Hebler R, Ebner A, et al. First human experience using pulsed electric fields for AF ablation and isolation of the pulmonary veins and posterior left atrium, AFS-2018-6, J Cardiovasc Electrophysiol. 2018;29:657–678. (abstr)

McElderry H, Walcott G, Viswanathan R, Long G, Sauter E, Mickelsen S. Safety of pulsed electric field ablation in direct application to the porcine esophagus. AFS-2018-7, J Cardiovasc Electrophysiol. 2018;29:657–678. (abstr)

2009 - 2021

Chang DC, Reese TS.
Changes in membrane structure induced by electroporation as revealed by rapid-freezing electron microscopy. Biophys J 1990;58:1–12.

Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B.
In Vivo Results of a New Focal Tissue Ablation Technique: Irreversible Electroporation. IEEE Transactions on Biomedical Engineering 2006;53:1409–1415.

Jourabchi N, Beroukhim K, Tafti BA, Kee ST, Lee EW.
Irreversible electroporation (NanoKnife) in cancer treatment. Gastrointestinal Intervention 2014;3:8–18.

Kotnik T, Kramar P, Pucihar G, Miklavčič D, Tarek SM.
Cell Membrane Electroporation— Part 1: The Phenomenon. IEEE Electr Insul Mag 2012;28:14–23.

Marszalek P, Liu DS, Tsong TY.
Schwan equation and transmembrane potential induced by alternating electric field. Biophysical Journal 1990;58:1053–1058.

Neumann E, M S-R, Y W, Hofschneider P.
Gene transfer into electric fields. EMBO J 1982;1:841–845.

Li W, Fan Q, Ji Z, Qiu X, Li Z,
The effects of irreversible electroporation on nerves, PLoS ONE, Vol. 6, Issue 4 (April 2011), e18331.

Maor E, Ivorra A, Rubinsky B,
Non-thermal irreversible electroporation: novel technology for vascular smooth muscle cells ablation, PLoS ONE Vol. 4, Issue 3 (March 2009) e4757. (abstr)

Bao N, Le TL, Cheng JX, Lu C,
Miucrofluidic electroporation of tumor and blood cells: observation of nucleus expansion and implications on selective analysis and purging of circulating tumor cells, Interg. Biol. (Camb)., 2 (2-3) (2010) 113 – 120.

Sano MB, Neal RE, Garcia PA, Gerber D, Robertson J, Davalos RV,
Towards the creation of decellularized organ constructs using irreversible electroporation and active mechanical perfusion, BioMedical Engineering Online, (2010) 9:83.

Neal RE II, Garcia PA, Kavmoudias H, Rosenfield F, Mclean CA, Earl V, Bergman J, Davalos RV, Thomson KR,
In vivo irreversible kidney electroporation: experimentally correlated numerical models, IEEE Trans. Biomed. Eng., 62(2) (Feb. 2015) 561 – 569.

Arena CB, Szot CS, Garcia PA, Rylander MN, Davalos RV,
A three-dimensional in vitro tumor platform for modeling therapeutic irreversible electroporation, Biophys. J., Vol. 103 (Nov. 2012) 2033 – 2042.

Kaminska I, Kotulska M, Stecka RV, Saczko J, Drag-Zelinska M, Wysocka T, Choromanska A, Nowicki R, Marczak J, Kulbacka J,
Elecetroporation-induced changes in normal immature rat myoblasts (H9C2), Gen. Physiol. Biophys., 31 (2012) 19 – 25.

Pré BC Du, Driel VJ Van, Wessel H Van, Loh P, Doevendans PA, Goldschmeding R, Wittkampf FH, Vink A.
Minimal coronary artery damage by myocardial electroporation ablation. Europace 2013;15:144–149.

Neven K, Driel V Van, Wessel H Van, Es R Van, Pré B Du, Doevendans PA, Wittkampf F.
Safety and feasibility of closed chest epicardial catheter ablation using electroporation. Circ Arrhythmia Electrophysiol 2014;7:913–919.

Neven K, Driel V Van, Wessel H Van, Es R Van, Doevendans PA, Wittkampf F.
Myocardial Lesion Size After Epicardial Electroporation Catheter Ablation After Subxiphoid Puncture. Circ Arrhythmia Electrophysiol 2014;7:728–733.

Neven K, Driel V Van, Wessel H Van, Es R Van, Doevendans PA, Wittkampf F.
Epicardial linear electroporation ablation and lesion size. Heart Rhythm 2014;11:1465–1470.

Driel VJHM van, Neven KGEJ, Wessel H van, Pré BC du, Vink A, Doevendans PAFM, Wittkampf FHM.
Pulmonary Vein Stenosis After Catheter Ablation. Circ Arrhythmia Electrophysiol 2014;7:734–738.

Driel VJHM Van, Neven K, Wessel H Van, Vink A, Doevendans PAFM, Wittkampf FHM.
Low vulnerability of the right phrenic nerve to electroporation ablation. Heart Rhythm 2015;12:1838–1844.

Wittkampf FH, Driel VJ Van, Wessel H Van, Vink A, Hof IE, Gründeman PF, Hauer RN, Loh P.
Feasibility of electroporation for the creation of pulmonary vein ostial lesions. J Cardiovasc Electrophysiol 2011;22:302–309.

Wittkampf FHM, Driel VJ Van, Wessel H Van, Neven KGEJ, Gründeman PF, Vink A, Loh P, Doevendans PA.
Myocardial lesion depth with circular electroporation ablation. Circ Arrhythmia Electrophysiol 2012;5:581–586.

For more information about The ADVENT Trial, including sites where enrollment is active, please CLICK HERE.

Boston Scientific Exercises Option to Acquire Farapulse, Inc.
Acquisition complements company's electrophysiology portfolio to include the only commercially available cardiac pulsed field ablation technology
Read More

FARAPULSE’s Pivotal ADVENT Trial underway with First Patients Treated with its Breakthrough Pulsed Field Ablation System to Treat Atrial Fibrillation
Read More

FARAPULSE Receives European Approval To Commercialize Its Leading Pulsed Field Ablation System To Treat Paroxysmal Atrial Fibrillation
Read More

FARAPULSE Pivotal Trial to Assess Its Leading Pulsed Field Ablation System for The Treatment of Atrial Fibrillation Receives FDA Conditional Approval
Read More

Boston Scientific Announces Expanded Investment and Exclusive Acquisition Option Agreement with Farapulse, Inc.
Read More

FARAPULSE’s Pioneering Clinical Results at HRS Link Compelling Longterm Outcomes to Established Safety and Lesion Durability Data
Read More

FARAPULSE Extensively Showcased at Leading AF Symposium
Company’s technology and clinical progress detailed across more than 12 lectures/posters
Read More

FARAPULSE featured prominently at 2019 HRS Scientific Sessions
Late Breaking Clinical Trial Presentation and concurrent JACC publication highlight FARAPULSE technology’s potential to achieve new standard of care in treating Atrial Fibrillation
Read More

FARAPULSE Receives FDA Breakthrough Designation for its Endocardial Pulsed Field Ablation System
Late Breaking Clinical Trial Presentation and concurrent JACC publication highlight FARAPULSE technology’s potential to achieve new standard of care in treating Atrial Fibrillation
Read More